Fintel reports that on January 7, 2025, TD Cowen initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation.

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene ...

Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...

CG Oncology, Inc. (CGON – Research Report) received a Buy rating and price target from TD Cowen analyst Tyler Van Buren today. The company’s ...

CG Oncology has taken the ribbon for the first biotech initial public offering (IPO) of the new year and its $380 million raise – which far outstrips the proceeds forecast – backs up the view ...

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) shares were down 6.9% during mid-day trading on Monday . The stock traded as low as $27.84 and last traded at $27.98. Approximately 108,925 shares ...

CG Oncology Inc. IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a ...

CG Oncology, Inc. (NASDAQ:CGON) reported positive results just about a week ago from its phase 3 BOND-003 study using its oncolytic immunotherapy candidate Cretostimogene for the treatment of BCG ...

IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone ...

On Thursday, CG Oncology, Inc. (NASDAQ:CGON) revealed topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CG Oncology Inc. IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a ...